| Jeffrey William Allman, DO | |
|
4370 W Main St, Dothan, AL 36305 | |
| (334) 793-5000 | |
| (334) 615-8419 |
| Full Name | Jeffrey William Allman |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 30 Years |
| Location | 4370 W Main St, Dothan, Alabama |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1104890995 | NPI | - | NPPES |
| 051515768 | Medicaid | AL | |
| 263894100 | Other | FLORIDA MEDICAID | |
| 51527560 | Other | AL | BCBS OF ALABAMA |
| P00055566 | Other | RAILROAD MEDICARE | |
| 1645702 | Other | LA | MEDICAID |
| 000833764E | Other | GEORGIA MEDICAID |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | DO.447 (Alabama) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Santa Rosa Medical Center | Milton, FL | Hospital |
| Atmore Community Hospital | Atmore, AL | Hospital |
| Andalusia Health | Andalusia, AL | Hospital |
| Bullock County Hospital | Union springs, AL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Floridian Emergency Specialists Llc | 3375682891 | 24 |
| Santa Rosa Hb Medical Services Llc | 4284089335 | 31 |
| Professional Resources Management, Inc. | 5597748350 | 6 |
| Moore Emergency Group, Llc | 9537421516 | 12 |
News Archive
The heart failure market is expected to grow from $3.7bn in 2018 to $22.1bn in 2028 across the eight major markets (8MM) at an impressive compound annual growth rate of 19.5%, according to GlobalData, a leading data and analytics company.
The idea that stem cells - special cells that divide to repair and generate tissues - might be the major determinant of cancer risk has provoked great debate in the scientific community.
BioDelivery Sciences International, Inc. today announced a positive meeting with the U.S. Food and Drug Administration (FDA), Meda and BDSI that occurred on Wednesday, July 21, 2010 to discuss significant modifications to the existing Risk Evaluation and Mitigation Strategy (REMS) program for ONSOLIS (fentanyl buccal soluble film).
Abbott announced today that it has received CE Mark approval for the world's first drug eluting bioresorbable vascular scaffold (BVS) for the treatment of coronary artery disease. Abbott's BVS device restores blood flow by opening a clogged vessel and providing support to the vessel until the device dissolves within approximately two years, leaving patients with a treated vessel free of a permanent metallic implant. Abbott's BVS device will be commercialized under the brand name ABSORB.
At Angelica, we are committed to meeting the highest standards of corporate citizenship by fulfilling our mission to offer healthcare providers superior services based on our high quality products, unsurpassed quality and service standards, and creative solutions. While we strive to achieve that mission in the communities where we do business, we embrace opportunities where we can support communities outside our geographical footprint through charitable activities.
› Verified 4 days ago
| Entity Name | Floridian Emergency Specialists Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710210695 PECOS PAC ID: 3375682891 Enrollment ID: O20091123000274 |
News Archive
The heart failure market is expected to grow from $3.7bn in 2018 to $22.1bn in 2028 across the eight major markets (8MM) at an impressive compound annual growth rate of 19.5%, according to GlobalData, a leading data and analytics company.
The idea that stem cells - special cells that divide to repair and generate tissues - might be the major determinant of cancer risk has provoked great debate in the scientific community.
BioDelivery Sciences International, Inc. today announced a positive meeting with the U.S. Food and Drug Administration (FDA), Meda and BDSI that occurred on Wednesday, July 21, 2010 to discuss significant modifications to the existing Risk Evaluation and Mitigation Strategy (REMS) program for ONSOLIS (fentanyl buccal soluble film).
Abbott announced today that it has received CE Mark approval for the world's first drug eluting bioresorbable vascular scaffold (BVS) for the treatment of coronary artery disease. Abbott's BVS device restores blood flow by opening a clogged vessel and providing support to the vessel until the device dissolves within approximately two years, leaving patients with a treated vessel free of a permanent metallic implant. Abbott's BVS device will be commercialized under the brand name ABSORB.
At Angelica, we are committed to meeting the highest standards of corporate citizenship by fulfilling our mission to offer healthcare providers superior services based on our high quality products, unsurpassed quality and service standards, and creative solutions. While we strive to achieve that mission in the communities where we do business, we embrace opportunities where we can support communities outside our geographical footprint through charitable activities.
› Verified 4 days ago
| Entity Name | Junco Emergency Physicians Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1740664713 PECOS PAC ID: 3072821172 Enrollment ID: O20151008001706 |
News Archive
The heart failure market is expected to grow from $3.7bn in 2018 to $22.1bn in 2028 across the eight major markets (8MM) at an impressive compound annual growth rate of 19.5%, according to GlobalData, a leading data and analytics company.
The idea that stem cells - special cells that divide to repair and generate tissues - might be the major determinant of cancer risk has provoked great debate in the scientific community.
BioDelivery Sciences International, Inc. today announced a positive meeting with the U.S. Food and Drug Administration (FDA), Meda and BDSI that occurred on Wednesday, July 21, 2010 to discuss significant modifications to the existing Risk Evaluation and Mitigation Strategy (REMS) program for ONSOLIS (fentanyl buccal soluble film).
Abbott announced today that it has received CE Mark approval for the world's first drug eluting bioresorbable vascular scaffold (BVS) for the treatment of coronary artery disease. Abbott's BVS device restores blood flow by opening a clogged vessel and providing support to the vessel until the device dissolves within approximately two years, leaving patients with a treated vessel free of a permanent metallic implant. Abbott's BVS device will be commercialized under the brand name ABSORB.
At Angelica, we are committed to meeting the highest standards of corporate citizenship by fulfilling our mission to offer healthcare providers superior services based on our high quality products, unsurpassed quality and service standards, and creative solutions. While we strive to achieve that mission in the communities where we do business, we embrace opportunities where we can support communities outside our geographical footprint through charitable activities.
› Verified 4 days ago
| Entity Name | App Of Florida Ed, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1407338932 PECOS PAC ID: 7012252299 Enrollment ID: O20181217000426 |
News Archive
The heart failure market is expected to grow from $3.7bn in 2018 to $22.1bn in 2028 across the eight major markets (8MM) at an impressive compound annual growth rate of 19.5%, according to GlobalData, a leading data and analytics company.
The idea that stem cells - special cells that divide to repair and generate tissues - might be the major determinant of cancer risk has provoked great debate in the scientific community.
BioDelivery Sciences International, Inc. today announced a positive meeting with the U.S. Food and Drug Administration (FDA), Meda and BDSI that occurred on Wednesday, July 21, 2010 to discuss significant modifications to the existing Risk Evaluation and Mitigation Strategy (REMS) program for ONSOLIS (fentanyl buccal soluble film).
Abbott announced today that it has received CE Mark approval for the world's first drug eluting bioresorbable vascular scaffold (BVS) for the treatment of coronary artery disease. Abbott's BVS device restores blood flow by opening a clogged vessel and providing support to the vessel until the device dissolves within approximately two years, leaving patients with a treated vessel free of a permanent metallic implant. Abbott's BVS device will be commercialized under the brand name ABSORB.
At Angelica, we are committed to meeting the highest standards of corporate citizenship by fulfilling our mission to offer healthcare providers superior services based on our high quality products, unsurpassed quality and service standards, and creative solutions. While we strive to achieve that mission in the communities where we do business, we embrace opportunities where we can support communities outside our geographical footprint through charitable activities.
› Verified 4 days ago
| Entity Name | Santa Rosa Hb Medical Services Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1982384988 PECOS PAC ID: 4284089335 Enrollment ID: O20231010004073 |
News Archive
The heart failure market is expected to grow from $3.7bn in 2018 to $22.1bn in 2028 across the eight major markets (8MM) at an impressive compound annual growth rate of 19.5%, according to GlobalData, a leading data and analytics company.
The idea that stem cells - special cells that divide to repair and generate tissues - might be the major determinant of cancer risk has provoked great debate in the scientific community.
BioDelivery Sciences International, Inc. today announced a positive meeting with the U.S. Food and Drug Administration (FDA), Meda and BDSI that occurred on Wednesday, July 21, 2010 to discuss significant modifications to the existing Risk Evaluation and Mitigation Strategy (REMS) program for ONSOLIS (fentanyl buccal soluble film).
Abbott announced today that it has received CE Mark approval for the world's first drug eluting bioresorbable vascular scaffold (BVS) for the treatment of coronary artery disease. Abbott's BVS device restores blood flow by opening a clogged vessel and providing support to the vessel until the device dissolves within approximately two years, leaving patients with a treated vessel free of a permanent metallic implant. Abbott's BVS device will be commercialized under the brand name ABSORB.
At Angelica, we are committed to meeting the highest standards of corporate citizenship by fulfilling our mission to offer healthcare providers superior services based on our high quality products, unsurpassed quality and service standards, and creative solutions. While we strive to achieve that mission in the communities where we do business, we embrace opportunities where we can support communities outside our geographical footprint through charitable activities.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jeffrey William Allman, DO Po Box 6907, Dothan, AL 36302 Ph: (334) 793-5000 | Jeffrey William Allman, DO 4370 W Main St, Dothan, AL 36305 Ph: (334) 793-5000 |
News Archive
The heart failure market is expected to grow from $3.7bn in 2018 to $22.1bn in 2028 across the eight major markets (8MM) at an impressive compound annual growth rate of 19.5%, according to GlobalData, a leading data and analytics company.
The idea that stem cells - special cells that divide to repair and generate tissues - might be the major determinant of cancer risk has provoked great debate in the scientific community.
BioDelivery Sciences International, Inc. today announced a positive meeting with the U.S. Food and Drug Administration (FDA), Meda and BDSI that occurred on Wednesday, July 21, 2010 to discuss significant modifications to the existing Risk Evaluation and Mitigation Strategy (REMS) program for ONSOLIS (fentanyl buccal soluble film).
Abbott announced today that it has received CE Mark approval for the world's first drug eluting bioresorbable vascular scaffold (BVS) for the treatment of coronary artery disease. Abbott's BVS device restores blood flow by opening a clogged vessel and providing support to the vessel until the device dissolves within approximately two years, leaving patients with a treated vessel free of a permanent metallic implant. Abbott's BVS device will be commercialized under the brand name ABSORB.
At Angelica, we are committed to meeting the highest standards of corporate citizenship by fulfilling our mission to offer healthcare providers superior services based on our high quality products, unsurpassed quality and service standards, and creative solutions. While we strive to achieve that mission in the communities where we do business, we embrace opportunities where we can support communities outside our geographical footprint through charitable activities.
› Verified 4 days ago
Dr. Mathew Glen Krista, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 4126 West Main Street, Dothan, AL 36305 Phone: 334-793-2120 Fax: 334-671-0228 | |
Dr. Patrick William Jones, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1108 Ross Clark Cir, Dothan, AL 36301 Phone: 334-793-8911 | |
Jesse Bryan Basford, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1108 Ross Clark Cir, Emergency Department, Dothan, AL 36301 Phone: 334-793-8111 | |
James C Jones, DO Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1108 Ross Clark Cir, Dothan, AL 36301 Phone: 334-793-8087 Fax: 334-793-8191 | |
Rick Marcus Weber, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1052 Ross Clark Circle, Dothan, AL 36303 Phone: 334-699-3600 Fax: 334-699-3601 | |
David W Williams, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 1108 Ross Clark Cir, Dothan, AL 36301 Phone: 334-793-8087 Fax: 334-793-8191 |